NCT06226402View on ClinicalTrials.gov

Effect of Nebulized and Intravenous Hypertonic Saline 3% on the Management of Patients With Acute Respiratory Distress Syndrome

NARecruitingINTERVENTIONAL
Enrollment

105

Participants

Timeline

Start Date

September 1, 2023

Primary Completion Date

September 1, 2024

Study Completion Date

September 1, 2024

Conditions
NebulizationHypertonic SalineAcute Respiratory Distress Syndrome
Interventions
DRUG

Hypertonic saline 3% nebulizer

Patients will receive the standard pharmacotherapy + hypertonic saline 3% (5ml) nebulizer /8hr.

DRUG

Intravenous hypertonic saline 3%

Patients will receive the standard pharmacotherapy + hypertonic saline 3% intravenous over 24 hours to maintain plasma Na level between 145-150 mEq/L.

Trial Locations (1)

31527

RECRUITING

Tanta University, Tanta

All Listed Sponsors
lead

Tanta University

OTHER